コンテンツへスキップ
Merck

HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis.

Circulation. Heart failure (2015-09-16)
Ludivine Renaud, Lillianne G Harris, Santhosh K Mani, Harinath Kasiganesan, James C Chou, Catalin F Baicu, An Van Laer, Adam W Akerman, Robert E Stroud, Jeffrey A Jones, Michael R Zile, Donald R Menick
要旨

MicroRNAs (miRNAs) and histone deacetylases (HDACs) serve a significant role in the pathogenesis of a variety of cardiovascular diseases. The transcriptional regulation of miRNAs is poorly understood in cardiac hypertrophy. We investigated whether the expression of miR-133a is epigenetically regulated by class I and IIb HDACs during hypertrophic remodeling. Transverse aortic constriction (TAC) was performed in CD1 mice to induce pressure overload hypertrophy. Mice were treated with class I and IIb HDAC inhibitor (HDACi) via drinking water for 2 and 4 weeks post TAC. miRNA expression was determined by real-time polymerase chain reaction. Echocardiography was performed at baseline and post TAC end points for structural and functional assessment. Chromatin immunoprecipitation was used to identify HDACs and transcription factors associated with miR-133a promoter. miR-133a expression was downregulated by 0.7- and 0.5-fold at 2 and 4 weeks post TAC, respectively, when compared with vehicle control (P<0.05). HDAC inhibition prevented this significant decrease 2 weeks post TAC and maintained miR-133a expression near vehicle control levels, which coincided with (1) a decrease in connective tissue growth factor expression, (2) a reduction in cardiac fibrosis and left atrium diameter (marker of end-diastolic pressure), suggesting an improvement in diastolic function. Chromatin immunoprecipitation analysis revealed that HDAC1 and HDAC2 are present on the miR-133a enhancer regions. The results reveal that HDACs play a role in the regulation of pressure overload-induced miR-133a downregulation. This work is the first to provide insight into an epigenetic-miRNA regulatory pathway in pressure overload-induced cardiac fibrosis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ジクロロメタン, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
ジクロロメタン, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
ジクロロメタン, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Sigma-Aldrich
ビス-トリス, ≥98.0% (titration)
Sigma-Aldrich
モノクロナール抗α-チューブリン マウス宿主抗体, clone DM1A, ascites fluid
SAFC
ビス-トリス
Sigma-Aldrich
ジクロロメタン, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Sigma-Aldrich
ジクロロメタン, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
ビス-トリス, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
ビス-トリス, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, ≥98.0%
Sigma-Aldrich
ジクロロメタン, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
7-アミノ-4-メチルクマリン, 99%
Sigma-Aldrich
ビス-トリス, BioXtra, ≥98.0% (titration)
Sigma-Aldrich
7-アミノ-4-メチルクマリン, Chromophore for substrates
Sigma-Aldrich
ジクロロメタン, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer
SAFC
ビス-トリス
Supelco
ジクロロメタン 溶液, contains 10 % (v/v) methanol
Sigma-Aldrich
ジクロロメタン, JIS special grade, ≥99.0%
Sigma-Aldrich
ジクロロメタン, SAJ first grade, ≥99.0%
Sigma-Aldrich
抗ヒストンH3抗体, 0.5 mg/mL, Upstate®
Sigma-Aldrich
ジクロロメタン, HPLC grade
Sigma-Aldrich
ジクロロメタン, suitable for HPLC, ≥99.9%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
ジクロロメタン, JIS 300, for residue analysis
Sigma-Aldrich
ジクロロメタン, JIS 5000, for residue analysis